Y Intercept Hong Kong Ltd Takes $70,000 Position in CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

Y Intercept Hong Kong Ltd purchased a new stake in CymaBay Therapeutics, Inc. (NASDAQ:CBAYGet Rating) in the second quarter, according to its most recent filing with the SEC. The fund purchased 23,644 shares of the biopharmaceutical company’s stock, valued at approximately $70,000.

A number of other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its holdings in shares of CymaBay Therapeutics by 2.7% in the 1st quarter. BlackRock Inc. now owns 5,466,209 shares of the biopharmaceutical company’s stock valued at $16,998,000 after acquiring an additional 142,081 shares during the last quarter. Vanguard Group Inc. grew its stake in CymaBay Therapeutics by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 3,842,376 shares of the biopharmaceutical company’s stock worth $11,950,000 after buying an additional 53,919 shares during the last quarter. State Street Corp lifted its stake in CymaBay Therapeutics by 1.8% in the first quarter. State Street Corp now owns 1,358,050 shares of the biopharmaceutical company’s stock valued at $4,224,000 after buying an additional 24,160 shares during the last quarter. Affinity Asset Advisors LLC lifted its stake in CymaBay Therapeutics by 13.4% in the first quarter. Affinity Asset Advisors LLC now owns 1,272,244 shares of the biopharmaceutical company’s stock valued at $3,957,000 after buying an additional 150,000 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in shares of CymaBay Therapeutics by 18.4% during the first quarter. Dimensional Fund Advisors LP now owns 940,806 shares of the biopharmaceutical company’s stock valued at $2,926,000 after acquiring an additional 145,965 shares during the period. 74.92% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of CymaBay Therapeutics in a report on Wednesday, October 12th. They set a “hold” rating for the company. One research analyst has rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, CymaBay Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $10.00.

CymaBay Therapeutics Stock Performance

Shares of CBAY opened at $3.55 on Monday. The company has a market cap of $300.61 million, a price-to-earnings ratio of -2.73 and a beta of 0.54. The firm has a fifty day moving average of $3.50 and a 200-day moving average of $3.07. CymaBay Therapeutics, Inc. has a 1 year low of $1.67 and a 1 year high of $4.55. The company has a debt-to-equity ratio of 1.00, a quick ratio of 13.27 and a current ratio of 13.27.

CymaBay Therapeutics (NASDAQ:CBAYGet Rating) last posted its quarterly earnings data on Thursday, August 11th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.30) by ($0.01). During the same period last year, the business earned ($0.34) EPS. As a group, equities analysts anticipate that CymaBay Therapeutics, Inc. will post -1.21 earnings per share for the current year.

About CymaBay Therapeutics

(Get Rating)

CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis.

Recommended Stories

Institutional Ownership by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.